Recent developments in transposon-mediated gene therapy

Expert Opinion on Biological Therapy

Volumn 12, Issue 7, 2012, Pages 841-858

  Di Matteo, Mario ^a   Belay, Eyayu ^b   Chuah, Marinee K ^a   Vandendriessche, Thierry ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Gene therapy; PiggyBac; Sleeping Beauty; Tol2; Transposon

Indexed keywords

BETA GLOBIN; BETA GLUCURONIDASE; CD135 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FUMARYLACETOACETASE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; INSULIN; INTERLEUKIN 11 RECEPTOR ALPHA; LEVO IDURONIDASE; RECOMBINANT BLOOD CLOTTING FACTOR 9; SMALL INTERFERING RNA;

CELL THERAPY; CRIGLER NAJJAR SYNDROME; DNA MODIFICATION; EX VIVO GENE TRANSFER; GENE DELIVERY SYSTEM; GENE TRANSFER; GENETIC DISORDER; GENOMICS; GLIOBLASTOMA; HEMATOPOIETIC STEM CELL; HEMOPHILIA B; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO GENE TRANSFER; INSULIN DEPENDENT DIABETES MELLITUS; LUNG FIBROSIS; MESENCHYMAL STEM CELL; MUCOPOLYSACCHARIDOSIS; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OSTEOSARCOMA; PIGGYBAC TRANSPOSON SYSTEM; PLURIPOTENT STEM CELL; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; SICKLE CELL ANEMIA; SKELETAL MUSCLE; SLEEPING BEAUTY TRANSPOSON SYSTEM; STEM CELL; TOL2 TRANSPOSON SYSTEM; TRANSPOSON; TYROSINEMIA;

CLINICAL TRIALS AS TOPIC; DNA TRANSPOSABLE ELEMENTS; GENE THERAPY; GENETIC VECTORS; HUMANS; VIRUS INTEGRATION;

EID: 84862204724     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.684875     Document Type: Review

References (194)

1. Aiuti A, Roncarolo MG. Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program 2009;682-9
2. Bainbridge JW, Ali RR. Success in sight: The eyes have it! Ocular gene therapy trials for LCA look promising. Gene Ther 2008;15:1191-2
3. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010;363:355-64
4. Baum C, von Kalle C, Staal FJ, et al. Chance or necessity?Insertional mutagenesis in gene therapy and its consequences. Mol Ther 2004;9:5-13
5. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80:148-58
6. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2011;11:321-30
7. VandenDriessche T. Gene therapy delivers. Hum Gene Ther 2009;20:1222-3
8. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 2005;54:3-20
9. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther 2010;18:674-83.. First clinical trial using transposons.
10. Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008;68:2961-71
11. Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 2005;6:299-310
12. Mates L, Izsvak Z, Ivics Z. Technology transfer from worms and flies to vertebrates: Transposition-based genome manipulations and their future perspectives. Genome Biol 2007;8(Suppl 1):S1
13. Koga A, Sakaizumi M, Hori H. Transposable elements in medaka fish. Zoolog Sci 2002;19:1-6
14. Fraser MJ, Ciszczon T, Elick T, et al. Precise excision of TTAA-specific lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera. Insect Mol Biol 1996;5:141-51
15. Ding S, Wu X, Li G, et al. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 2005;122:473-83.. First description of efficient transposition of PB transposon in mammalian cells and mice.
16. VandenDriessche T, Ivics Z, Izsvak Z, et al. Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood 2009;114:1461-8
17. Izsvak Z, Ivics Z. Sleeping beauty transposition: Biology and applications for molecular therapy. Mol Ther 2004;9:147-56
18. Mc CB. The origin and behavior of mutable loci in maize. Proc Natl Acad Sci USA 1950;36:344-55
19. Biemont C. Are transposable elements simply silenced or are they under house arrest?Trends Genet 2009;25:333-4
20. Plasterk RH, Izsvak Z, Ivics Z. Resident aliens: The Tc1/mariner superfamily of transposable elements. Trends Genet 1999;15:326-32
21. Ivics Z, Hackett PB, Plasterk RH, et al. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997;91:501-10.. First description of the SB transposon system as a novel gene transfer paradigm.
22. Fraser MJ, Cary L, Boonvisudhi K, et al. Assay for movement of Lepidopteran transposon IFP2 in insect cells using a baculovirus genome as a target DNA. Virology 1995;211:397-407
23. Ivics Z, Izsvak Z. Transposons for gene therapy!. Curr Gene Ther 2006;6(5):593-607
24. Aronovich EL, McIvor RS, Hackett PB. The Sleeping Beauty transposon system: A non-viral vector for gene therapy. Hum Mol Genet 2011;20:R14-20
25. Ivics Z, Izsvak Z. The expanding universe of transposon technologies for gene and cell engineering. Mob DNA 2010;1:25
26. Ivics Z, Izsvak Z. Nonviral gene delivery with the sleeping beauty transposon system. Hum Gene Ther 22: 2011;1043-51
27. Williams DA. Sleeping beauty vector system moves toward human trials in the United States. Mol Ther 2008;16:1515-16
28. Izsvak Z, Khare D, Behlke J, et al. Involvement of a bifunctional, paired-like DNA-binding domain and a transpositional enhancer in Sleeping Beauty transposition. J Biol Chem 2002;277:34581-8
29. Cui Z, Geurts AM, Liu G, et al. Structure-function analysis of the inverted terminal repeats of the sleeping beauty transposon. J Mol Biol 2002;318:1221-35
30. Walisko O, Schorn A, Rolfs F, et al. Transcriptional activities of the Sleeping Beauty transposon and shielding its genetic cargo with insulators. Mol Ther 2008;16:359-69. Demonstration that safety of transposons can be improved by incorporating insulators into the transposon backbone.
31. Ivics Z, Izsvak Z, Minter A, et al. Identification of functional domains and evolution of Tc1-like transposable elements. Proc Natl Acad Sci USA 1996;93:5008-13
32. Vigdal TJ, Kaufman CD, Izsvak Z, et al. Common physical properties of DNA affecting target site selection of sleeping beauty and other Tc1/mariner transposable elements. J Mol Biol 2002;323:441-52
33. Yant SR, Wu X, Huang Y, et al. High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol 2005;25:2085-94
34. Hartl DL, Lohe AR, Lozovskaya ER. Regulation of the transposable element mariner. Genetica 1997;100:177-84
35. Geurts AM, Yang Y, Clark KJ, et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther 2003;8:108-17
36. Lohe AR, Hartl DL. Autoregulation of mariner transposase activity by overproduction and dominant-negative complementation. Mol Biol Evol 1996;13:549-55
37. Yant SR, Park J, Huang Y, et al. Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: Critical residues for DNA binding and hyperactivity in mammalian cells. Mol Cell Biol 2004;24:9239-47
38. Baus J, Liu L, Heggestad AD, et al. Hyperactive transposase mutants of the Sleeping Beauty transposon. Mol Ther 2005;12:1148-56
39. Mates L, Chuah MK, Belay E, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 2009;41:753-61.. Latest generation SB technology obtained by molecular evolution and first validation of in vivo gene marking with transposon-modified CD34+ hematopoietic stem/progenitor cells (HSCs).
40. Izsvak Z, Ivics Z, Plasterk RH. Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol 2000;302:93-102
41. Karsi A, Moav B, Hackett P, et al. Effects of insert size on transposition efficiency of the sleeping beauty transposon in mouse cells. Mar Biotechnol (NY) 2001;3:241-5
42. Zayed H, Izsvak Z, Walisko O, et al. Development of hyperactive sleeping beauty transposon vectors by mutational analysis. Mol Ther 2004;9:292-304. Expanding the cargo capacity of SB "sandwich configuration".
43. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921
44. Fraser MJ, Brusca JS, Smith GE, et al. Transposon-mediated mutagenesis of a baculovirus. Virology 1985;145:356-61.. First description of the PB system.
45. Cary LC, Goebel M, Corsaro BG, et al. Transposon mutagenesis of baculoviruses: Analysis of Trichoplusia ni transposon IFP2 insertions within the FP-locus of nuclear polyhedrosis viruses. Virology 1989;172:156-69
46. Wilson MH, Coates CJ, George AL Jr. PiggyBac transposon-mediated gene transfer in human cells. Mol Ther 2007;15:139-45
47. Handler AM. Use of the piggyBac transposon for germ-line transformation of insects. Insect Biochem Mol Biol 2002;32:1211-20
48. Wu SC, Meir YJ, Coates CJ, et al. piggyBac is a flexible and highly active transposon as compared to sleeping beauty, Tol2, and Mos1 in mammalian cells. Proc Natl Acad Sci USA 2006;103:15008-13
49. Cadinanos J, Bradley A. Generation of an inducible and optimized piggyBac transposon system. Nucleic Acids Res 2007;35:e87
50. Yusa K, Zhou L, Li MA, et al. A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci USA 2011;108;1531:6. First hyperactive PB system.
51. Li X, Harrell RA, Handler AM, et al. piggyBac internal sequences are necessary for efficient transformation of target genomes. Insect Mol Biol 2005;14:17-30
52. Li X, Lobo N, Bauser CA, et al. The minimum internal and external sequence requirements for transposition of the eukaryotic transformation vector piggyBac. Mol Genet Genomics 2001;266:190-8
53. Lacoste A, Berenshteyn F, Brivanlou AH. An efficient and reversible transposable system for gene delivery and lineage-specific differentiation in human embryonic stem cells. Cell Stem Cell 2009;5:332-42
54. Meir YJ, Weirauch MT, Yang HS, et al. Genome-wide target profiling of piggyBac and Tol2 in HEK 293: Pros and cons for gene discovery and gene therapy. BMC Biotechnol 2011;11:28
55. Li MA, Turner DJ, Ning Z, et al. Mobilization of giant piggyBac transposons in the mouse genome. Nucleic Acids Res 2011;39:e148
56. Liang Q, Kong J, Stalker J, et al. Chromosomal mobilization and reintegration of Sleeping Beauty and PiggyBac transposons. Genesis 2009;47:404-8
57. Grabundzija I, Irgang M, Mates L, et al. Comparative analysis of transposable element vector systems in human cells. Mol Ther 2010;18:1200-9
58. Belay E, Matrai J, Acosta-Sanchez A, et al. Novel hyperactive transposons for genetic modification of induced pluripotent and adult stem cells: A nonviral paradigm for coaxed differentiation. Stem Cells 2010;28:1760-71
59. Doherty JE, Huye LE, Yusa K, et al. Hyperactive piggyBac Gene transfer in human cells and in vivo. Hum Gene Ther 2012;23:311-20. Description of the most efficient hyPB to date in primary cells.
60. Yant SR, Huang Y, Akache B, et al. Site-directed transposon integration in human cells. Nucleic Acids Res 2007;35:e50. Site-directed SB integration into human cells.
61. Zayed H, Izsvak Z, Khare D, et al. The DNA-bending protein HMGB1 is a cellular cofactor of Sleeping Beauty transposition. Nucleic Acids Res 2003;31:2313-22
62. Walisko O, Izsvak Z, Szabo K, et al. Sleeping Beauty transposase modulates cell-cycle progression through interaction with Miz-1. Proc Natl Acad Sci USA 2006;103:4062-7
63. Koga A, Suzuki M, Inagaki H, et al. Transposable element in fish. Nature 1996;383:30.. First description of Tol2 transposon.
64. Kawakami K. Tol2: A versatile gene transfer vector in vertebrates. Genome Biol 2007;8(Suppl 1):S7
65. Kawakami K, Noda T. Transposition of the Tol2 element, an Ac-like element from the Japanese medaka fish Oryzias latipes, in mouse embryonic stem cells. Genetics 2004;166:895-9
66. Parinov S, Kondrichin I, Korzh V, et al. Tol2 transposon-mediated enhancer trap to identify developmentally regulated zebrafish genes in vivo. Dev Dyn 2004;231:449-59
67. Keng VW, Ryan BJ, Wangensteen KJ, et al. Efficient transposition of Tol2 in the mouse germline. Genetics 2009;183:1565-73
68. Suster ML, Sumiyama K, Kawakami K. Transposon-mediated BAC transgenesis in zebrafish and mice. BMC Genomics 2009;10:477
69. Urasaki A, Morvan G, Kawakami K. Functional dissection of the Tol2 transposable element identified the minimal cis-sequence and a highly repetitive sequence in the subterminal region essential for transposition. Genetics 2006;174:639-49
70. Moldt B, Miskey C, Staunstrup NH, et al. Comparative genomic integration profiling of Sleeping Beauty transposons mobilized with high efficacy from integrase-defective lentiviral vectors in primary human cells. Mol Ther 2011;19:1499-510
71. Nightingale SJ, Hollis RP, Pepper KA, et al. Transient gene expression by nonintegrating lentiviral vectors. Mol Ther 2006;13:1121-32
72. Staunstrup NH, Moldt B, Mates L, et al. Hybrid lentivirus-transposon vectors with a random integration profile in human cells. Mol Ther 2009;17:1205-14
73. Vink CA, Gaspar HB, Gabriel R, et al. Sleeping beauty transposition from nonintegrating lentivirus. Mol Ther 2009;17:1197-204
74. Galla M, Schambach A, Falk CS, et al. Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery. Nucleic Acids Res 2011;39:7147-60
75. de Silva S, Lotta LT Jr., Burris CA, et al. Virion-associated cofactor high-mobility group DNA-binding protein-1 facilitates transposition from the herpes simplex virus/Sleeping Beauty amplicon vector platform. Hum Gene Ther 2010;21:1615-22
76. de Silva S, Mastrangelo MA, Lotta LT Jr., et al. Herpes simplex virus/Sleeping Beauty vector-based embryonic gene transfer using the HSB5 mutant: Loss of apparent transposition hyperactivity in vivo. Hum Gene Ther 2010;21:1603-13
77. Bowers WJ, Mastrangelo MA, Howard DF, et al. Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector. Mol Ther 2006;13:580-8
78. Yant SR, Ehrhardt A, Mikkelsen JG, et al. Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol 2002;20:999-1005
79. Hausl MA, Zhang W, Muther N, et al. Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol Ther 2010;18:1896-906
80. Hollis RP, Nightingale SJ, Wang X, et al. Stable gene transfer to human CD34(+) hematopoietic cells using the Sleeping Beauty transposon. Exp Hematol 2006;34:1333-43
81. Podetz-Pedersen KM, Bell JB, Steele TW, et al. Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons. Hum Gene Ther 2010;21:210-20
82. Kren BT, Unger GM, Sjeklocha L, et al. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest 2009;119:2086-99
83. Yant SR, Meuse L, Chiu W, et al. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000;25:35-41.. First description of transposon-based gene therapy in vivo.
84. Aronovich EL, Bell JB, Belur LR, et al. Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: Implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med 2007;9:403-15
85. He CX, Shi D, Wu WJ, et al. Insulin expression in livers of diabetic mice mediated by hydrodynamics-based administration. World J Gastroenterol 2004;10:567-72
86. Suda T, Liu D. Hydrodynamic gene delivery: Its principles and applications. Mol Ther 2007;15:2063-9
87. Bell JB, Podetz-Pedersen KM, Aronovich EL, et al. Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. Nat Protoc 2007;2:3153-65
88. Yoshino H, Hashizume K, Kobayashi E. Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume. Gene Ther 2006;13:1696-702
89. Herweijer H, Wolff JA. Gene therapy progress and prospects: Hydrodynamic gene delivery. Gene Ther 2007;14:99-107
90. Izsvak Z, Hackett PB, Cooper LJ, et al. Translating Sleeping Beauty transposition into cellular therapies: Victories and challenges. Bioessays 2010;32:756-67
91. Suda T, Suda K, Liu D. Computer-assisted hydrodynamic gene delivery. Mol Ther 2008;16:1098-104
92. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118:3132-42
93. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302:415-19
94. Berry C, Hannenhalli S, Leipzig J, et al. Selection of target sites for mobile DNA integration in the human genome. PLoS Comput Biol 2006;2:e157
95. Huang X, Guo H, Tammana S, et al. Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. Mol Ther 2010;18:1803-13
96. Hackett CS, Geurts AM, Hackett PB. Predicting preferential DNA vector insertion sites: Implications for functional genomics and gene therapy. Genome Biol 2007;8(Suppl 1):S12
97. Nakai H, Montini E, Fuess S, et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 2003;34:297-302
98. Bushman F, Lewinski M, Ciuffi A, et al. Genome-wide analysis of retroviral DNA integration. Nat Rev Microbiol 2005;3:848-58
99. Schroder AR, Shinn P, Chen H, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002;110:521-9
100. Wu X, Li Y, Crise B, et al. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003;300:1749-51
101. Galvan DL, Nakazawa Y, Kaja A, et al. Genome-wide mapping of PiggyBac transposon integrations in primary human T cells. J Immunother 2009;32:837-44
102. Modlich U, Baum C. Preventing and exploiting the oncogenic potential of integrating gene vectors. J Clin Invest 2009;119:755-8
103. Montini E, Cesana D, Schmidt M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009;119:964-75
104. Voigt K, Izsvak Z, Ivics Z. Targeted gene insertion for molecular medicine. J Mol Med (Berl) 2008;86:1205-19
105. Wilson MH, Kaminski JM, George AL Jr. Functional zinc finger/sleeping beauty transposase chimeras exhibit attenuated overproduction inhibition. FEBS Lett 2005;579:6205-9
106. Ivics Z, Katzer A, Stuwe EE, et al. Targeted Sleeping Beauty transposition in human cells. Mol Ther 2007;15:1137-44. Site-directed SB integration into human cells.
107. Wilson MH, George AL Jr. Designing and testing chimeric zinc finger transposases. Methods Mol Biol 2010; 649:353-63
108. Kettlun C, Galvan DL, George AL Jr., et al. Manipulating piggyBac transposon chromosomal integration site selection in human cells. Mol Ther 2011;19:1636-44. First targeted integration of PB in human cells.
109. Cornu TI, Thibodeau-Beganny S, Guhl E, et al. DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger nucleases. Mol Ther 2008;16:352-8
110. Yusa K, Rad R, Takeda J, et al. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods 2009;6:363-9.. First use of transposons for iPS cells generation.
111. Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009;458:771-5.. First use of transposons for iPS cells generation.
112. Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009;458:766-70.. First use of transposons for iPS cells generation.
113. Manuri PV, Wilson MH, Maiti SN, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther 2010; 21:427-37
114. Nakazawa Y, Huye LE, Salsman VS, et al. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther 2011;19:2133-43
115. Huye LE, Nakazawa Y, Patel MP, et al. Combining mTor inhibitors with rapamycin-resistant T cells: A two-pronged approach to tumor elimination. Mol Ther 2011;19:2239-48
116. Bank A. Hematopoietic stem cell gene therapy: Selecting only the best. J Clin Invest 2003;112:1478-80
117. Karlsson S, Ooka A, Woods NB. Development of gene therapy for blood disorders by gene transfer into haematopoietic stem cells. Haemophilia 2002;8:255-60
118. Miyoshi H. Gene delivery to hematopoietic stem cells using lentiviral vectors. Methods Mol Biol 2004;246:429-38
119. Aiuti A. Advances in gene therapy for ADA-deficient SCID. Curr Opin Mol Ther 2002;4:515-22
120. Gillet JP, Macadangdang B, Fathke RL, et al. The development of gene therapy: From monogenic recessive disorders to complex diseases such as cancer. Methods Mol Biol 2009;542:5-54
121. Tamhane M, Akkina R. Stable gene transfer of CCR5 and CXCR4 siRNAs by sleeping beauty transposon system to confer HIV-1 resistance. AIDS Res Ther 2008;5:16
122. Liu L, Liu H, Mah C, et al. Indoleamine 2,3-dioxygenase attenuates inhibitor development in gene-therapy-treated hemophilia A mice. Gene Ther 2009;16:724-33
123. Kohn DB. Gene therapy for childhood immunological diseases. Bone Marrow Transplant 2008;41:199-205
124. Weissinger F, Reimer P, Waessa T, et al. Gene transfer in purified human hematopoietic peripheral-blood stem cells by means of electroporation without prestimulation. J Lab Clin Med 2003;141:138-49
125. Floch V, Le Bolc'h G, Audrezet MP, et al. Cationic phosphonolipids as non viral vectors for DNA transfection in hematopoietic cell lines and CD34+ cells. Blood Cells Mol Dis 1997;23:69-87
126. Xue X, Huang X, Nodland SE, et al. Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood 2009;114:1319-30
127. Sumiyoshi T, Holt NG, Hollis RP, et al. Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system. Hum Gene Ther 2009;20:1607-26
128. Sjeklocha LM, Park CW, Wong PY, et al. Erythroid-specific expression of beta-globin from Sleeping Beauty-transduced human hematopoietic progenitor cells. PLoS One 2011;6:e29110
129. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007;211:27-35
130. Bartholomew A, Sher D, Sosler S, et al. Stem cell transplantation eliminates alloantibody in a highly sensitized patient. Transplantation 2001;72:1653-5
131. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-9
132. Van Damme A, Vanden Driessche T, Collen D, et al. Bone marrow stromal cells as targets for gene therapy. Curr Gene Ther 2002;2:195-209
133. Gnecchi M, Melo LG. Bone marrow-derived mesenchymal stem cells: Isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol 2009;482:281-94
134. Tolar J, Nauta AJ, Osborn MJ, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007;25:371-9
135. Bosch P, Musgrave DS, Lee JY, et al. Osteoprogenitor cells within skeletal muscle. J Orthop Res 2000;18:933-44
136. Qu Z, Balkir L, van Deutekom JC, et al. Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol 1998;142:1257-67
137. Goncalves MA, Holkers M, Cudre-Mauroux C, et al. Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: Robust dystrophin synthesis in duchenne muscular dystrophy muscle cells. Mol Ther 2006;13:976-86
138. Fernandes S, van Rijen HV, Forest V, et al. Cardiac cell therapy: Overexpression of connexin43 in skeletal myoblasts and prevention of ventricular arrhythmias. J Cell Mol Med 2009;13:3703-12
139. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76
140. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-3
141. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-17
142. Nakagawa M, Koyanagi M, Tanabe K, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008;26:101-6
143. Hochedlinger K, Yamada Y, Beard C, et al. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005;121:465-77
144. Foster KW, Liu Z, Nail CD, et al. Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene 2005;24:1491-500
145. Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008;322:949-53
146. Okita K, Matsumura Y, Sato Y, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods 2011;8:409-12
147. Narsinh KH, Jia F, Robbins RC, et al. Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nat Protoc 2011;6:78-88
148. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618-30
149. Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration. Science 2008;322:945-9
150. Ban H, Nishishita N, Fusaki N, et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci USA 2011;108:14234-9
151. Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009;4:472-6
152. Mitra R, Fain-Thornton J, Craig NL. piggyBac can bypass DNA synthesis during cut and paste transposition. EMBO J 2008;27:1097-109
153. Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011;478:391-4
154. Karumbayaram S, Novitch BG, Patterson M, et al. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells 2009;27:806-11
155. Darabi R, Santos FN, Perlingeiro RC. The therapeutic potential of embryonic and adult stem cells for skeletal muscle regeneration. Stem Cell Rev 2008;4:217-25
156. Chuah MK, Vandendriessche T. Gene therapy for haemophilia "A" and "B": Efficacy, safety and immune consequences. Bull Mem Acad R Med Belg 2007;162:357-61
157. Nguyen TH, Ferry N. Gene therapy for liver enzyme deficiencies: What have we learned from models for Crigler-Najjar and tyrosinemia?Expert Rev Gastroenterol Hepatol 2007;1:155-71
158. Li Q, Murphree SS, Willer SS, et al. Gene therapy with bilirubin-UDP-glucuronosyltransferase in the Gunn rat model of Crigler-Najjar syndrome type 1. Hum Gene Ther 1998;9:497-505
159. Zhang W, Ke W, Wu SS, et al. An adenovirus-delivered peptide aptamer C1-1 targeting the core protein of hepatitis B virus inhibits viral DNA replication and production in vitro and in vivo. Peptides 2009;30:1816-21
160. Bell JB, Aronovich EL, Schreifels JM, et al. Duration of expression and activity of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA delivery. Mol Ther 18: 2010;1796-802
161. Saridey SK, Liu L, Doherty JE, et al. PiggyBac transposon-based inducible gene expression in vivo after somatic cell gene transfer. Mol Ther 2009;17:2115-20
162. Nakanishi H, Higuchi Y, Kawakami S, et al. piggyBac transposon-mediated long-term gene expression in mice. Mol Ther 2010;18:707-14
163. Vandendriessche T, Thorrez L, Acosta-Sanchez A, et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 2007;5:16-24
164. Ohlfest JR, Frandsen JL, Fritz S, et al. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood 2005;105:2691-8
165. Follenzi A, Battaglia M, Lombardo A, et al. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 2004;103:3700-9
166. Kebriaei P, Huls H, Jena B, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 2012;[Epub ahead of print]
167. Huang X, Guo H, Kang J, et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther 2008;16:580-9
168. Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther 2004;10:5-18
169. Fischer A, Hacein-Bey S, Cavazzana-Calvo M. Gene therapy of severe combined immunodeficiencies. Nat Rev Immunol 2002;2:615-21
170. Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004;199:885-94
171. Jin Z, Maiti S, Huls H, et al. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther 2011;18:849-56
172. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: Tools, trials and tribulations. Nat Rev Immunol 2009;9:704-16
173. Newrzela S, Cornils K, Li Z, et al. Resistance of mature T cells to oncogene transformation. Blood 2008;112:2278-86
174. Bonini C, Grez M, Traversari C, et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 2003;9:367-9
175. Khorsandi SE, Bachellier P, Weber JC, et al. Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human. Cancer Gene Ther 2008;15:225-30
176. Woodard LE, Keravala A, Jung WE, et al. Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma. PLoS One 2010;5:e11367
177. Dalsgaard T, Moldt B, Sharma N, et al. Shielding of sleeping beauty DNA transposon-delivered transgene cassettes by heterologous insulators in early embryonal cells. Mol Ther 2009;17:121-30
178. Mikkelsen JG, Yant SR, Meuse L, et al. Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. Mol Ther 2003;8:654-65
179. Montini E, Held PK, Noll M, et al. In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol Ther 2002;6:759-69
180. Liu L, Sanz S, Heggestad AD, et al. Endothelial targeting of the Sleeping Beauty transposon within lung. Mol Ther 2004;10:97-105
181. Belur LR, Frandsen JL, Dupuy AJ, et al. Gene insertion and long-term expression in lung mediated by the Sleeping Beauty transposon system. Mol Ther 2003;8:501-7
182. Zhu J, Kren BT, Park CW, et al. Erythroid-specific expression of beta-globin by the sleeping beauty transposon for Sickle cell disease. Biochemistry 2007;46:6844-58
183. Chen ZJ, Kren BT, Wong PY, et al. Sleeping Beauty-mediated downregulation of huntingtin expression by RNA interference. Biochem Biophys Res Commun 2005;329:646-52
184. Liu L, Mah C, Fletcher BS. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon. Mol Ther 2006c;13:1006-15
185. Ohlfest JR, Frandsen JL, Fritz S, et al. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood 2005b;105:2691-8
186. Wu A, Oh S, Ericson K, et al. Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma. Cancer Gene Ther 2007;14:550-60
187. Ohlfest JR, Demorest ZL, Motooka Y, et al. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 2005a;12:778-88
188. Liu L, Liu H, Visner G, Fletcher BS. Sleeping Beauty-mediated eNOS gene therapy attenuates monocrotaline-induced pulmonary hypertension in rats. FASEB J 2006b;20:2594-6
189. Liu H, Liu L, Fletcher BS, Visner GA. Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis. FASEB J 2006a;20:2384-6
190. Wang X, Sarkar DP, Mani P, et al. Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposon. Hepatology 2009;50:815-24
191. Aronovich EL, Bell JB, Khan SA, et al. Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther 2009;17:1136-44
192. Huang G, Yu L, Cooper LJ, et al. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res 2012;72:271-81
193. Belur LR, Podetz-Pedersen K, Frandsen J, et al. Lung-directed gene therapy in mice using the nonviral Sleeping Beauty transposon system. Nat Protoc. 2007;2:3146-52
194. Ortiz-Urda S, Lin Q, Yant SR, et al. Sustainable correction of junctional epidermolysis bullosa via transposonmediated nonviral gene transfer. Gene Ther. 2003;10:1099-104